Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vei...
Sichuan Kelun Pharmaceutical reported revenue of 21.81 billion CNY for fiscal year 2024, up 1.7% from fiscal year 2023, and net income of 2.94 billion CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 4.69 billion CNY, down 16.3% from a year before. Its largest business segment, Other Business Segments, brought in 65% of segment revenue in fiscal year 2025; Eastern China was the largest region with 27%.
Figures from company filings; latest fiscal year ended December 31, 2024.
No profile data available.